Earnings Call Summary | Cibus Inc(CBUS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cibus Inc(CBUS.US) Q1 2024 Earnings Conference
The following is a summary of the Cibus, Inc. (CBUS) Q1 2024 Earnings Call Transcript:
以下是Cibus, Inc.(CBUS)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Cibus reported a net loss of $27 million for Q1 2024, increasing significantly from a net loss of $5.4 million in the previous year.
As of March 31, 2024, the company held cash reserves amounting to $24.5 million.
Cibus had a monthly burn rate of approximately $4.5 million, using about $13.5 million of cash from operations in the past quarter.
The company managed to raise $6.2 million via regular equity sales in the first quarter, and an additional $9.5 million in the second quarter to date.
Cibus報告稱,2024年第一季度淨虧損2700萬美元,較上一年的540萬美元淨虧損大幅增加。
截至2024年3月31日,該公司持有的現金儲備總額爲2450萬美元。
Cibus的每月消耗率約爲450萬美元,在過去一個季度使用了約1,350萬美元的運營現金。
該公司在第一季度設法通過定期股票銷售籌集了620萬美元,迄今爲止在第二季度又籌集了950萬美元。
Business Progress:
業務進展:
Cibus moved to commercial stage, licensing its developed traits to seed companies for annual royalties.
They have signed contracts with major firms, including Nutrien and Interoc.
Cibus expanded its RTDS gene editing platforms to cover canola, rice, and weed, and aims to include soybean by the end of the year.
The company's technological achievements, particularly its 'trait machine', has earned it recognition from Fast Company Magazine.
Cibus has made significant progress with gene editing technologies, securing four agreements with rice customers in the USA and Latin America.
The company has widened its patent portfolio to ensure security for its technologies and expects to hit further milestones in the upcoming quarter.
Cibus進入商業階段,將其開發特徵許可給種子公司,收取年度特許權使用費。
他們已經與包括Nutrien和Interoc在內的大公司簽訂了合同。
Cibus將其RTDS基因編輯平台擴展到涵蓋油菜、水稻和大麻,並計劃在年底之前將大豆包括在內。
該公司的技術成就,特別是 “特徵機器”,贏得了《快公司》雜誌的認可。
Cibus在基因編輯技術方面取得了重大進展,與美國和拉丁美洲的大米客戶達成了四項協議。
該公司擴大了其專利組合,以確保其技術的安全性,並預計將在下個季度實現進一步的里程碑。
More details: Cibus Inc IR
更多詳情: Cibus Inc IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。